Clinical trials: Benign Essential Blepharospasm
- Condition Benign Essential Blepharospasm
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Cervical Dystonia, Blepharospasm
A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm
This study is a retrospective chart review to evaluate the doses of botulinum Type A toxins BOTOX® (onabotulinumtoxinA) and Xeomin® (incobotulinumtoxinA) used for the treatment of Cervical Dystonia and Blepharospasm in clinical…
- Trial name
- NCT01814774
- Testing
- No Intervention
- Where
- 2 sites in Norway, United Kingdom
- Volunteers
- 48 people
- Sponsor
- Allergan
Blepharospasm, Torticollis
MDs on Botox Utility (MOBILITY)
The MOBILITY Project is a prospective, non-randomized, observational, multi-centre evaluation of Health Utility via the SF-12® Health Survey Scores and the SF-6D in patients receiving BOTOX® for therapeutic use.
- Conditions
- Blepharospasm, Torticollis, Strabismus, Muscle Spasticity
- Trial name
- NCT00535938
- Testing
- botulinum toxin type A
- Where
- Canada
- Volunteers
- 1,372 people
- Sponsor
- Allergan
Blepharospasm
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm
Patients received one injection with incobotulinumtoxinA (Xeomin) or placebo at baseline. Thereafter, all patients who entered the Open-Label Extension Period (OLEX) received up to five injection sessions of incobotulinumtoxinA…
- Trial name
- NCT00406367
- Testing
- incobotulinumtoxinA (Xeomin)
- Where
- 2 sites in United States, Canada
- Volunteers
- 109 people
- Sponsor
- Merz Pharmaceuticals GmbH
Bilateral Blepharospasm (BEB)
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Abnormal Contraction or Twitch of the Eyelid
This phase 3 study will serve to collect efficacy and safety data of two different doses of NT 201 in subjects suffering from Bilateral Blepharospasm (BEB) who are BTX treatment-naïve.
- Trial name
- NCT01896895
- Testing
- IncobulinumtoxinA (Xeomin), 25 Units, IncobotulinumtoxinA (Xeomin), 12.5 Units, IncobotulinumtoxinA (Xeomin), 35 Units
- Where
- 11 sites in Greece, Malaysia and 1 more
- Volunteers
- 61 people
- Sponsor
- Merz Pharmaceuticals GmbH
Blepharospasm
Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm
This pilot study estimates the treatment effects of two different types of botulinum toxin type A in the treatment of Blepharospasm.
- Trial name
- NCT00761592
- Testing
- Botulinum Toxin Type A 900kDa, Botulinum Toxin Type A 150kDa
- Where
- 3 sites in Germany
- Volunteers
- 65 people
- Sponsor
- Allergan